


Curriculum vitae



Title, first name and surname	Prof. Dr. med. Christoffer Gebhardt	
Address	Department of Dermatology and Venereology University Skin Cancer Center Hamburg University Medical Center Hamburg-Eppendorf (UKE) Martinistrasse 52 (W14) 20246 Hamburg, Germany	
Phone/Fax No. E-mail	Phone: +49 (0)40-7410 57626 Fax: +49 (0)40-7410 57545 E-mail: ch.gebhardt@uke.de	
Present Positions	since 11/2017 since 09/2021 since 09/2022 since 01/2025	Vice Chair of Department of Dermatology and Venereology Head of University Skin Cancer Center Hamburg Head of Experimental Dermatology University Professor of Dermato-Oncology Coordinator of Research Program “Dissemination & Metastasis”, University Comprehensive Cancer Center Hamburg (UCCH) Head of Fleur Hiege Center for Skin Cancer Research, Hamburg Executive Board Member, University Comprehensive Cancer Center Hamburg (UCCH)
Previous employments	2012 – 2017 2012 - 2017	Attending Physician, Department of Dermatology, University Medical Center Mannheim Head of Research Group, Clinical Cooperation Unit Dermatooncology, German Cancer Research Center (DKFZ)
Education (Board Certifications, Residency, Thesis, Medical School)	2014 2011 2008 – 2011 2005 – 2011 2004 2003 – 2007 1999 – 2005 2003 2001	Board Certificate in Medical Tumor Therapy Board Certificate in Dermatology and Venereology Deputy Coordinator, Skin Cancer Center at the University Hospital Heidelberg and at the National Center for Tumor Diseases (NCT), Heidelberg Resident, Department of Dermatology, University of Heidelberg Full Approbation (01-OCT-2004) Postdoc and Project Leader, German Cancer Research Center (DKFZ), Heidelberg Doctoral thesis: “Identification and Analysis of tumor-associated c-Fos/AP-1 target genes in skin carcinogenesis”, German Cancer Research Center (DKFZ), Heidelberg (<i>summa cum laude</i>) Medical Student (PJ), The University of Texas M.D. Anderson Cancer Center, Houston (USA) Summer Student, Lincoln’s Inn Fields, Imperial Cancer Research Fund, London (UK)

	2000 – 2001	Medical Student (MBChB), University of Aberdeen, Scotland (UK)	
	1997 – 2004	Medical Student, University of Heidelberg Medical School, Germany	
	1986 – 1996	Gymnasium Philippinum, Marburg	
Awards (selected):	2009	Oscar Gans Award of the German Dermatological Society (DDG)	
	2009	Egon Macher Award of the German Society of Experimental Dermatology (ADF)	
	2008	Fleur Hiege Award (ADO and <i>Hiege Stiftung</i>)	
	2007 – 2008	Young Investigator Research Scholarship, German Dermatological Society (DDG)	
	2007	Young Investigator Award, University of Heidelberg	
	1998 – 2004	Scholarship of the German National Merit Foundation (<i>Studienstiftung des deutschen Volkes</i>)	
Membership of scientific societies	AACR, ADF, ADO, ADP, AEK, ASCO, DDG, DKG, EADO, EADV, EORTC, ESDR, ESMO, MWS, NVKH, SMR		
Positions in scientific societies/ journals	Since 2026	Congress Co-Chair (elect), 16th European Post-Chicago Melanoma / Skin Cancer Meeting 2026	
	Since 2025	Board Member, European Association of Dermato-Oncology (EADO)	
	Since 2025	Scientific Board Member, Melanoma World Society (MWS)	
	Since 2023	Section Editor/Editor, Journal of the European Academy of Dermatology and Venereology (JEADV)	
	Since 2022	Executive Board Member, German Society of Dermato-Oncology (ADO/DeCOG)	
	2017-2022	Executive Board Member, German Society of Experimental Dermatology (ADF)	
	Since 2015	Section Editor, Journal der Deutschen Dermatologischen Gesellschaft (JDDG)	
	02-10/2017	President, Cancer Society Mannheim (OAK)	
Positions in private foundations/ public organisations	Since 07/2023	Mentor for the German National Merit Foundation (<i>Studienstiftung des deutschen Volkes</i>)	
	Since 10/2022	Executive board member, Roggenbuck Stiftung (Private Cancer Research Foundation)	
	Since 11/2020	Executive board member, Hiege Stiftung (German Skin Cancer Foundation)	
Clinical research experience	since 2007	more than 90 clinical trials in Dermatooncology as Principle Investigator	Phases I-II-III-IV including IIT
Private Industry /Start-Up	Since 2021	Co-founder of Dermagnostix GmbH	
	Since 2020	Co-founder of Dermagnostix R&D GmbH	
Place/Date:	Hamburg, 22-MAY-2025		

List of Publications (May 22nd 2025)

Publication Statistics (Google Scholar): **Citations: 10,294** **h-index: 39** **i10-index: 68**
First Authorships: 15 **Senior Authorships: 18**

Original Reports

1. Bechter O, Loquai C, Champiat S, Baurain JF, Grob JJ, Utikal J, Rottey S, Berrocal A, Hassel JC, Arance A, Sanmamed MF, Boers-Sonderen M, Gastman B, **Gebhardt C**, Delafontaine B, Sahin U, Türeci Ö, Brueck P, Abbadessa G, Marpadga R, Lee H, Yang Y, Buday B, Di Genova G, Wang H, Xia B, Lee JS, Lebbe C. A phase 1, first-in-human, dose-escalation, expansion trial of cytokine encoding synthetic mRNA-mixture alone or with cemiplimab in advanced solid tumors. Clin Cancer Res. 2025 Mar 28. doi: 10.1158/1078-0432.CCR-24-1983.
2. Reinhard S, Utikal JS, Zaremba A, Lodde G, von Wasielewski I, Klespe KC, Meier F, Haferkamp S, Kähler KC, Herbst R, **Gebhardt C**, Sindrilaru A, Dippel E, Angela Y, Mohr P, Pfoehler C, Forscher A, Kaatz M, Schell B, Gesierich A, Loquai C, Hassel JC, Ulrich J, Meiss F, Schley G, Heinzerling LM, Sachse M, Welzel J, Weishaupt C, Sunderkötter C, Michl C, Lindhof HH, Kreuter A, Heppt MV, Wenk S, Mauch C, Berking C, Nedwed AS, Gutzmer R, Leiter U, Schadendorf D, Ugurel S, Weichenthal M, Haist M, Fleischer MI, Lang B, Grabbe S, Stege H. First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG. Eur J Cancer. 2025 Mar 15;220:115356. doi: 10.1016/j.ejca.2025.115356.
3. Weichenthal M, Ellebaek E, Mangana J, Asher N, Gavrilova I, Kandolf L, Ugurel S, Hausschild A, Meier F, Leiter U, Livingstone E, **Gebhardt C**, Gutzmer R, Ruhlmann CH, Mahncke-Guldbrandt L, Haslund CA, Kopec S, Teterycz P, Bender M, Poudroux W, Muñoz-Couselo E, Berciano-Guerrero MA, Shalamanova G, DePalo DK, Brozić JM, Chiarion-Sileni V, Arance A, Ziogas D, Robert C, van de Velde AO, Gassama AA, Shapira R, BenBetzalel G, Grynberg S, Ramelyte E, Bertoldo F, DelPrete V, Gaudy-Marqueste C, Mohr P, Dummer R, Ascierto PA, Gogas H, Espinosa E, Lebbé C, Rutkowski P, Haanen J, Schadendorf D, Svane IM; EUMelaReg Consortium Members. Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study. Eur J Cancer. 2025 Mar 7;220:115339. doi: 10.1016/j.ejca.2025.115339.
4. Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, **Gebhardt C**, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19.
5. Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea AM, **Gebhardt C**, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P; Melanoma World Society Study Group. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. Lancet Oncol. 2025 Jan;26(1):12-14. doi: 10.1016/S1470-2045(24)00627-2.
6. Melzer YF, Fergen NL, Mess C, Stadler JC, Geidel G, Schwietzer YA, Kött J, Pantel K, Schneider SW, Utikal J, Wladykowski E, Vidal-Y-Sy S, Bauer AT*, **Gebhardt C***. Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition. Transl Oncol. 2024 Dec 18;52:102224. doi: 10.1016/j.tranon.2024.102224. (* shared authorship)

7. Kött J, Zell T, Zimmermann N, Rünger A, Smit DJ, Abeck F, Geidel G, Hansen-Abeck I, Heidrich I, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, Zimmer L, Livingstone E, Wasielewski IV, Mohr P, Meier F, Haferkamp S, Drexler K, Herbst R, Kellner I, Utikal J, Wohlfeil SA, Pföhler C, Adam L, Terheyden P, Ulrich J, Meiss F, Möbes M, Welzel J, Schilling B, Ziller F, Kaatz M, Kreuter A, Sindrilaru A, Dippel E, Sachse M, Weishaupt C, Hüning S, Heinzerling L, Loquai C, Schley G, Gambichler T, Löffler H, Grabbe S, Schultz E, Devereux N, Hassel JC, Simon JC, Raap U, Assaf C, Klemke CD, Sunderkötter C, Hofmann SC, Wenk S, Tronnier M, Thies S, Heppt MV, Eggermont A, Schulze HJ, Zouboulis CC, Tüting T, Bauer AT, Schneider SW, **Gebhardt C**. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg. *Eur J Cancer*. 2025 Jan;214:115159. doi: 10.1016/j.ejca.2024.115159.
8. Christalle E, Zeh S, Führes H, Schellhorn A, Hahlweg P, Zill JM, Härter M, Bokemeyer C, Gallinat J, **Gebhardt C**, Magnussen C, Müller V, Schmalstieg-Bahr K, Strahl A, Kriston L, Scholl I. Through the patients' eyes: psychometric evaluation of the 64-item version of the Experienced Patient-Centeredness Questionnaire (EPAT-64). *BMJ Qual Saf*. 2024 Oct 16:bmjqs-2024-017434. doi: 10.1136/bmjqs-2024-017434.
9. Wohlfeil SA, Kranzmann L, Weiß C, von Wasielewski I, Klespe KC, Kähler KC, Weichenthal M, Schadendorf D, Zimmer L, Mohr P, Meier F, Pfoehler C, Berking C, Heppt MV, Herbst R, Kreuter A, Gutzmer R, Ulrich J, Meiss F, **Gebhardt C**, Dippel E, Leiter U, Schilling B, Ugurel S, Utikal J. Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg. *Int J Cancer*. 2024 Jul 8. doi: 10.1002/ijc.35078.
10. Sementsov M, Ott L, Kött J, Sartori A, Lusque A, Degenhardt S, Segier B, Heidrich I, Volkmer B, Greinert R, Mohr P, Simon R, Stadler JC, Irwin D, Koch C, Andreas A, Deitert B, Thewes V, Trumpp A, Schneeweiss A, Belloum Y, Peine S, Wikman H, Riethdorf S, Schneider SW, **Gebhardt C***, Pantel K*, Keller L*. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma. *EMBO Mol Med*. 2024 Jul;16(7):1560-1578. doi: 10.1038/s44321-024-00082-6. (* shared authorship)
11. Geidel G, Parnian N, Meß C, Schlepper N, Rünger A, Heidrich I, Hansen I, Smit DJ, Menz A, Pantel K, Schneider SW, Kött J, **Gebhardt C**. Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma. *J Eur Acad Dermatol Venereol*. 2024 Oct;38(10):2017-2023. doi: 10.1111/jdv.20177.
12. Kött J, Hoehne IL, Heidrich I, Zimmermann N, Reese KL, Zell T, Geidel G, Rünger A, Schneider SW, Pantel K, Smit DJ, **Gebhardt C**. High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy. *Cancers (Basel)*. 2024 Apr 29;16(9):1737. doi: 10.3390/cancers16091737.
13. Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, **Gebhardt C**, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. *EClinicalMedicine*. 2024 Mar 27;71:102564. doi: 10.1016/j.eclinm.2024.102564.
14. Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, **Gebhardt C**, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-

mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. *EClinicalMedicine*. 2023 Oct 31;65:102290. doi: 10.1016/j.eclim.2023.102290.

15. Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, Mohr P, Kähler KC, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, Gutzmer R, Debus D, Schilling B, Kreuter A, Ulrich J, Meiss F, Herbst R, Forschner A, Leiter U, Pfoehler C, Kaatz M, Ziller F, Hassel JC, Tronnier M, Sachse M, Dippel E, Terheyden P, Berking C, Heppt MV, Kiecker F, Haferkamp S, **Gebhardt C**, Simon JC, Grabbe S, Loquai C. Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. *J Immunother Cancer*. 2023 Sep;11(9):e007630.
16. Hassel JC, Berking C, Forschner A, **Gebhardt C**, Heinzerling L, Meier F, Ochsenreither S, Siveke J, Hauschild A, Schadendorf D. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp. *Eur J Cancer*. 2023 Sep;191:112986
17. Stadler JC, Keller L, Mess C, Bauer AT, Koett J, Geidel G, Heidrich I, Vidal-Y-Sy S, Andreas A, Stramaglia C, Sementsov M, Haberstroh W, Deitert B, Hoehne IL, Reschke R, Haalck T, Pantel K*, **Gebhardt C***, Schneider SW*. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors. *J Immunother Cancer*. 2023 May;11(5):e006456. doi: 10.1136/jitc-2022-006456. (* shared authorship)
18. Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, Forschner A, Leiter U, Ulrich J, Utikal J, Welzel J, Kaatz M, **Gebhardt C**, Herbst R, Sindrilaru A, Dippel E, Sachse M, Meiss F, Heinzerling L, Haferkamp S, Weishaupt C, Löffler H, Kreft S, Griewank K, Livingstone E, Schadendorf D, Ugurel S, Zimmer L. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. *Eur J Cancer*. 2023 Jul;188:140-151. doi: 10.1016/j.ejca.2023.04.008.
19. Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, **Gebhardt C**, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. *J Immunother Cancer*. 2023 Apr;11(4):e005828.
20. Glutsch V, Schummer P, Kneitz H, Gesierich A, Goebeler M, Klein D, Posch C, **Gebhardt C**, Haferkamp S, Zimmer L, Becker JC, Leiter U, Weichenthal M, Schadendorf D, Ugurel S, Schilling B. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. *J Immunother Cancer*. 2022 Nov;10(11):e005930.
21. Ammann NL, Schwietzer YF, Mess C, Stadler JC, Geidel G, Kött J, Pantel K, Schneider SW, Utikal J, Bauer AT, **Gebhardt C**. Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. *Cancers (Basel)*. 2022 Nov 18;14(22):5676.
22. Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, Ugurel S, Placke JM, Weichenthal M, Gutzmer R, Leiter U, Kaatz M, Haferkamp S, Berking C, Heppt M, Tschechne B, Schummer P, **Gebhardt C**, Grabbe S, Loquai C. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. *Cancers (Basel)*. 2022 Nov 11;14(22):5543.
23. DeTemple VK, Hassel JC, Sachse MM, Grimmelmann I, Leiter U, **Gebhardt C**, Eckardt J, Pföhler C, Angela Y, Hübbe H, Gutzmer R. Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients. *Cancers (Basel)*. 2022 Nov 7;14(21):5469.

24. Liu X, Wang Y, Bauer AT, Kirschfink M, Ding P, **Gebhardt C**, Borsig L, Tüting T, Renné T, Häffner K, Hu W, Schneider SW, Gorzelanny C. Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels. *Proc Natl Acad Sci U S A*. 2022 Aug 16;119(33).
25. Tizek L, Schuster B, **Gebhardt C**, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N. Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany. *J Dtsch Dermatol Ges*. 2022 Mar;20(3):287-295.
26. Stary G, Fabri M, **Gebhardt C**, Eming R, Matthias J, Vorobyev A, Efferm M, Strobl J, Günther C, Zielinski C, Dudziak D, Géraud C, Raker V, Butze M, Zhao F, Wang Y, Gerloff D, Bertschi NL, Gaffal E, Buhl T. Meeting Report: 47th Annual Meeting of the "Arbeitsgemeinschaft Dermatologische Forschung". *Exp Dermatol*. 2022 Mar 1.
27. Blomen CL, Kött J, Hartung TI, Torster LK, **Gebhardt C**. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? *Cancers (Basel)*. 2021 Dec 20;13(24):6390
28. Ascierto PA, Orlova K, Grignani G, Dudzisz-Śledź M, Fenig E, Chiarion Sileni V, Fazio N, Samimi M, Mortier L, **Gebhardt C**, Kramkimel N, Steven N, Bechter O, Arance A, Benincasa E, Kostkova L, Costa N, Lorigan P. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. *Int J Cancer*, 2021 Dec 1;149(11):1926-1934
29. Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; **IMCgp100-202 Investigators**. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *N Engl J Med*. 2021 Sep 23;385(13):1196-1206.
30. Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, Dücker P, Dummer R, Emmert S, Elsner P, Enk A, **Gebhardt C**, Gesierich A, Goebeler M, Goerdts S, Goetze S, Gutzmer R, Haferkamp S, Hansel G, Hassel JC, Heinzerling L, Kähler KC, Kaume KM, Krapf W, Kreuzberg N, Lehmann P, Livingstone E, Löffler H, Loquai C, Mauch C, Mangana J, Meier F, Meissner M, Moritz RKC, Maul LV, Müller V, Mohr P, Navarini A, Van Nguyen A, Pfeiffer C, Pföhler C, Posch C, Richtig E, Rompel R, Sachse MM, Sauder S, Schadendorf D, Schatton K, Schulze HJ, Schultz E, Schilling B, Schmuth M, Simon JC, Streit M, Terheyden P, Thiem A, Tüting T, Welzel J, Weyandt G, Wesselmann U, Wollina U, Ziemer M, Zimmer L, Zutt M, Berking C, Schlaak M, Heppt MV; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma). Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). *J Cancer Res Clin Oncol*. 2021 Jun;147(6):1763-1771.
31. Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse SA, Lamszus K, West-phal M, Müller V, Glatzel M, Matschke J, **Gebhardt C**, Schneider SW, Belczacka I, Volkmer B, Greinert R, Yaspo ML, Harter PN, Pantel K, Wikman H. CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. *Int J Mol Sci*. 2021 Jun 29;22(13):6993.
32. Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer SH, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen VA, **Gebhardt C**, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler TK. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer*. 2021 May;9(5):e002350.
33. Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, **Gebhardt C**, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E.

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. *Cancers (Basel)*. 2021 May 12;13(10):2319.

34. **Gebhardt C**, Simon SCS, Weber R, Gries M, Mun DH, Reinhard R, Holland-Letz T, Umansky V, Utikal J. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. *Cell Immunol*. 2021 Feb;360:104274.
35. Wessely A, Steeb T, Berking C, Schlaak M, Heppt MV; **German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma)**. Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. *Eur J Cancer*. 2021 Jan;143:43-45.
36. **Gebhardt C**, Ascierto P, Atkinson V, Corrie P, Dummer R, Schadendorf D. The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. *Eur J Cancer*. 2020 Oct;138:68-76
37. Schneegans S, Lück L, Besler K, Bluhm L, Stadler JC, Staub J, Greinert R, Volkmer B, Kubista M, **Gebhardt C**, Sartori A, Irwin D, Serkkola E, Af Hällström T, Lianidou E, Sprenger-Haussels M, Hussong M, Mohr P, Schneider SW, Shaffer J, Pantel K, Wikman H. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. *Mol Oncol*. 2020 May;14(5):1001-1015
38. Wagner NB, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V, Kemper C, Kehrel C, Funder A, Lichtenberger R, Sucker A, Herpel E, Holland-Letz T, Schadendorf D, Garbe C, Umansky V, Utikal J, **Gebhardt C**. Tumor Microenvironment-Derived S100A8/A9 Is a Novel Prognostic Biomarker for Advanced Melanoma Patients and During Immunotherapy With anti-PD-1 Antibodies. *J Immunother Cancer*. 2019 Dec 5;7(1):343.
39. Gaffal E, Eming R, Fabri M, **Gebhardt C**, Stary G, Eyerich S, Hölzel M, Kosnopfel C, Neubert E, Rauer D, Rodríguez E, Thiem A, von Meyenn L, Buhl T. 46th annual congress of the "Arbeitsgemeinschaft Dermatologische Forschung" in Munich, Germany. *Exp Dermatol*. 2019 Sep;28(9):1094-1099.
40. Orouji E, Federico A, Larribère L, Novak D, Lipka DB, Assenov Y, Sachindra S, Hüser L, Granados K, **Gebhardt C**, Plass C, Umansky V, Utikal J. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. *Int J Cancer*. 2019 Dec 15;145(12):3462-3477.
41. Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; **Collaborators**. Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. *Eur J Cancer*. 2019 May;113:47-54.
42. Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; **Collaborators**. A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. *Eur J Cancer*. 2019 Apr;111:148-154.
43. Schilling B, Martens A, Geukes Foppen MH, **Gebhardt C**, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. *Cancer Immunol Immunother*. 2019 May;68(5):765-772.
44. Jäger K, Larribère L, Wu H, Weiss C, **Gebhardt C**, Utikal J. Expression of Neural Crest Markers GLDC and ERFI1 is Correlated with Melanoma Prognosis. *Cancers (Basel)*. 2019 Jan 11;11(1):76.
45. Loser K, Eming R, Eyerich K, **Gebhardt C**, Ludwig R, Baghin V, Baurecht H, Forsthuber A, Glodde N, Schmidt E, Schmidt T, Shridhar N, Simon B, Gaffal E. 45th meeting of the Arbeitsgemeinschaft Dermatologische Forschung. *Exp Dermatol*. 2018 Jul;27(7):798-802.

46. Machiraju E, Moll I, **Gebhardt C**, Sucker A, Buder-Bakhaya K, Schadendorf D, Hassel JC. STAT5 Expression Correlates With Recurrence and Survival in Melanoma Patients Treated With Interferon- α . *Melanoma Res*, 28 (3), 204-210 Jun 2018
47. Haselmann V*, **Gebhardt C***, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. *Clin Chem*. 2018 May;64(5):830-842. (* shared authorship)
48. Birgin E, **Gebhardt C**, Hetjens S, Fischer S, Rückert F, Reichenberger MA. Extracorporeal Shock Wave Therapy Enhances Receptor for Advanced Glycated End-Product-Dependent Flap Survival and Angiogenesis. *Ann Plast Surg*. 2018 Apr;80(4):424-431.
49. Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, **Gebhardt C**, Schulze TJ, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V. CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. *Cancer Res*. 2018 Jan 1;78(1):157-167.
50. Dollt C, Becker K, Michel J, Melchers S, Weis CA, Schledzewski K, Krewer A, Kloss L, **Gebhardt C**, Utikal J, Schmieder A. The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation. *Oncotarget*. 2017 Oct 10;8(61):103682-103692.
51. Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, **Gebhardt C**, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity*. 2017 Oct 17;47(4):789-802.e9.
52. Kumar V, Fleming T, Terjung S, Gorzelanny C, **Gebhardt C**, Agrawal R, Mall MA, Ranzinger J, Zeier M, Madhusudhan T, Ranjan S, Isermann B, Liesz A, Deshpande D, Häring HU, Biswas SK, Reynolds PR, Hammes HP, Peperkok R, Angel P, Herzig S, Nawroth PP. Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair. *Nucleic Acids Res*. 2017 Oct 13;45(18):10595-10613.
53. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksman O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, **Gebhardt C**, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. *Nature*. 2017 Jul 13;547(7662):222-226.
54. Bernhardt M, Novak D, Assenov Y, Orouji E, Knappe N, Weina K, Reith M, Larribere L, **Gebhardt C**, Plass C, Umansky V, Utikal J. Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. *Stem Cell Reports*. 2017 May 9;8(5):1379-1391.
55. Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE, Espinet E, Herpel E, Menuchin A, Chang-Claude J, Hoffmeister M, **Gebhardt C**, Brenner H, Trumpp A, Siebel CW, Hecker M, Utikal J, Sprinzak D, Fischer A. Endothelial Notch1 Activity Facilitates Metastasis. *Cancer Cell*. 2017 Mar 13;31(3):355-367.
56. Umansky V, Blattner C, **Gebhardt C**, Utikal J. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. *Cancer Immunol Immunother*. 2017 Aug;66(8):1015-1023.
57. Griewank KG, Koelsche C, Wenz F, Giordano F, **Gebhardt C**. Melanocytoma vs. Melanoma: a diagnosis based on histopathological or genetic analysis? *J Neurosurg*. 2016 Sep;126(3):1026-1027.
58. Baum C, Weiss C, **Gebhardt C**, Utikal J, Marx A, Koenen W, Géraud C. Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas. *Int J Cancer*, 140 (8), 1907-1917 2017 Apr 15

59. Desch A, **Gebhardt C**, Utikal J, Schneider SW. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. *Int J Cancer*. 2017 Feb 15;140(4):914-921.
60. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, **Gebhardt C**, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hossers G, Garbe C, Wolchok JD. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. *Clin Cancer Res*. 2016 Nov 15;22(22):5487-5496.
61. Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, **Gebhardt C**, Fujii H, Nakashima C, Nonomura Y, Kabashima K, Dummer R, Contassot E, French LE. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. *Sci Rep*. 2016 Jul 18;6:29914.
62. Weina K, Wu H, Knappe N, Orouji E, Novak D, Bernhardt M, Hüser L, Larribère L, Umansky V, **Gebhardt C**, Utikal J. TGF- β induces SOX2 expression in a time-dependent manner in human melanoma cells. *Pigment Cell Melanoma Res*. 2016 Jul;29(4):453-8.
63. Orouji E, Orouji A, Gaiser T, Larribère L, **Gebhardt C**, Utikal J. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. *Int J Cancer*. 2016 May 1;138(9):2257-62.
64. Knappe N, Novak D, Weina K, Bernhardt M, Reith M, Larribere L, Hölzel M, Tüting T, **Gebhardt C**, Umansky V, Utikal J. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. *Stem Cells*. 2016 Apr;34(4):832-46.
65. **Gebhardt C**, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. *J Dtsch Dermatol Ges*. 2016 Feb;14(2):158-64.
66. **Gebhardt C**, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Umansky L, Sucker A, Schadendorf D, Utikal J, Umansky V. Innate Immune Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. *Clin Cancer Res*. 2016 Dec 15;21(24):5453-9.
67. Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, **Gebhardt C**. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. *Int J Cancer*. 2015 Dec 1;137(11):2607-17.
68. Pfirschke C, **Gebhardt C**, Zörnig I, Pritsch M, Eichmüller SB, Jäger D, Enk A, Beckhove P. T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. *Cancer Immunol Immunother*. 2015 Nov;64(11):1369-81.
69. Jiang H, **Gebhardt C**, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. *Int J Cancer*. 2015 May 15;136(10):2352-60.
70. Bernhardt M, Orouji E, Larribere L, **Gebhardt C**, Utikal J. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. *Clin Cancer Res*. 2014 May 1;20(9):2498-9.
71. Riehl A, Bauer T, Brors B, Busch H, Mark R, Németh J, **Gebhardt C**, Bierhaus A, Nawroth P, Eils R, König R, Angel P, Hess J. Identification of the RAGE-dependent gene regulatory network in a mouse model of skin inflammation. *BMC Genomics*. 2010 Oct 5;11:537.
72. Németh J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, **Gebhardt C**, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. *Hepatology*. 2009 Oct;50(4):1251-62.
73. **Gebhardt C**, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P. RAGE signaling sustains inflammation and promotes tumor development. *J Exp Med*. 2008 Feb 18;205(2):275-85.

74. Rhiemeier V, Breitenbach U, Richter KH, **Gebhardt C**, Vogt I, Hartenstein B, Fürstenberger G, Mauch C, Hess J, Angel P. A novel aspartic proteinase-like gene expressed in stratified epithelia and squamous cell carcinoma of the skin. *Am J Pathol.* 2006 Apr;168(4):1354-64.
75. **Gebhardt C***, Breitenbach U*, Richter KH, Fürstenberger G, Mauch C, Angel P, Hess J. c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesis. *Am J Pathol.* 2005 Jul;167(1):243-53.
76. Schlingemann J, Hess J, Wrobel G, Breitenbach U, **Gebhardt C**, Steinlein P, Kramer H, Fürstenberger G, Hahn M, Angel P, Lichter P. Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. *Int J Cancer.* 2003 May 10;104(6):699-708.
77. Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, **Gebhardt C**, Henderson R, Robinson MJ, Hogg N. Myeloid cell function in MRP-14 (S100A9) null mice. *Mol Cell Biol.* 2003 Apr;23(7):2564-76.
78. **Gebhardt C**, Breitenbach U, Tuckermann JP, Dittrich BT, Richter KH, Angel P. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. *Oncogene.* 2002 Jun 20;21(27):4266-76.
79. Breitenbach U, Tuckermann JP, **Gebhardt C**, Richter KH, Fürstenberger G, Christofori G, Angel P. Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis. *J Invest Dermatol.* 2001 Sep;117(3):634-40.

Case Reports

1. Geidel G, Menz A, Grotenrath FM, Rünge A, Kött J, Schneider SW, **Gebhardt C**, Booken N. Severe overlap of morphea and lichen sclerosus after anti-PD-L1 immunotherapy in small cell lung cancer. *J Dtsch Dermatol Ges.* 2024 Dec 8. doi: 10.1111/ddg.15599.
2. Hansen I, **Gebhardt C**, Booken N, Schneider SW. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma. *J Dtsch Dermatol Ges.* 2024 Feb 20. doi: 10.1111/ddg.15340.
3. Geidel G, Abeck F, Hansen I, Kött J, Heidrich I, Rünge A, Hildebrandt L, **Gebhardt C**. Sepsis-like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma. *J Eur Acad Dermatol Venereol.* 2023 Dec 7.
4. Geidel G, Adam L, Rünge A, Menz A, Kött J, Haalck T, **Gebhardt C**. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma. *J Eur Acad Dermatol Venereol.* 2023 Jul 17. doi: 10.1111/jdv.19344.
5. Hansen I, Heidrich I, Abeck F, Kött J, Booken N, **Gebhardt C**, Schneider SW. Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab. *J Eur Acad Dermatol Venereol.* 2023 May;37(5):e621-e623. doi: 10.1111/jdv.18780.
6. Geidel G, Rünge A, Schneider SW, **Gebhardt C**. Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case re-port. *J Eur Acad Dermatol Venereol.* 2022 Jan;36 Suppl 1:49-52.
7. Ammann NL, Geidel G, Schneider SW, **Gebhardt C**. Adjuvant pembrolizumab-related hyperprogression in stage III melanoma. *J Dtsch Dermatol Ges* 2021 Sep;19(9):1341-1345.
8. Reinhard R, **Gebhardt C**, Maurier N, Larribère L, Orouji A, Utikal J. Multiple Epidermotropic Melanoma Metastases Developing During BRAF and MEK Inhibitor Therapy. *JAAD Case Rep.* 2018 Jan 16;4(2):129-131. doi: 10.1016/j.jdc.2017.09.007.
9. Reinhard R, **Gebhardt C**, Schmieder A, Umansky V, Utikal J. Recurrent tattoo reactions in a patient treated with BRAF- and MEK-inhibitors. *J Eur Acad Dermatol Venereol.* 2017 Aug;31(8):e375-e377.

10. Hoffmann M, Koelsche C, Seiz-Rosenhagen M, Mai S, Lohr F, Reuss D, Wenz F, **Gebhardt C**, Giordano FA. The GNAQ in the haystack: intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman. *J Neurosurg*. 2016 Jul;125(1):53-6.
11. **Gebhardt C**, Ziegler B, Stadler S, Goerdts S, Utikal J. Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapy. *Br J Dermatol*. 2015 Apr;172(4):1156-8.
12. **Gebhardt C**, Staub J, Schmieder A, Goerdts S, Utikal J. Multiple White Cysts on Face and Trunk of a Melanoma Patient Treated with Vemurafenib. *Acta Derm Venereol*. 2015 Jan;95(1):96-7.
13. Orouji E, Ziegler B, Umansky V, **Gebhardt C**, Utikal J. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. *Medicine (Baltimore)*. 2014 Dec;93(28):e161.

Reviews/Commentaries

1. Kött J, **Gebhardt C**. Biomarker in der adjuvanten und neoadjuvanten Therapie des Melanoms. *Die Dermatologie*, 1-4 2025
2. **Gebhardt C**. Bridging the gap: From clinical intuition to structured cutaneous squamous cell carcinoma classification. *J Eur Acad Dermatol Venereol*. 2025 Mar;39(3):461-462.
3. Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, Smit DJ, Hansen I, Abeck F, Schadendorf D, Eggermont A, Puig S, Hauschild A, **Gebhardt C**. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy. *Eur J Cancer*. 2024 May;202:113989. doi: 10.1016/j.ejca.2024.113989.
4. **Gebhardt C**. Age matters: Rethinking SLNB's reliability in melanoma mortality prediction. *J Eur Acad Dermatol Venereol*. 2024 Apr;38(4):639-640. doi: 10.1111/jdv.19878.
5. **Gebhardt C**, Eyerich K, Garzorz-Stark N. Status quo and future perspectives of molecular diagnostics in dermatology. *J Dtsch Dermatol Ges*. 2023 Apr;21(4):415-418. doi: 10.1111/ddg.15010.
6. Rünger A, Schadendorf D, Hauschild A, **Gebhardt C**. Immune checkpoint blockade for organ-transplant recipients with cancer: A review. *Eur J Cancer*. 2022 Nov;175:326-335. doi: 10.1016/j.ejca.2022.08.010.
7. Heppt MV, **Gebhardt C**, Hassel JC, Alter M, Gutzmer R, Leiter U, Berking C. Long-term management of advanced basal cell carcinoma: current challenges and future perspectives. *Cancers (Basel)*. 2022 Sep 20;14(19):4547. doi: 10.3390/cancers14194547.
8. Geidel G, Heidrich I, Kött J, Schneider SW, Pantel K, **Gebhardt C**. Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. *NPJ Precis Oncol*. 2022 Mar 23;6(1):17.
9. Stadler JC, Belloum Y, Deitert B, Sementsov M, Heidrich I, **Gebhardt C**, Keller L, Pantel K. Current and Future Clinical Applications of ctDNA in Immuno-Oncology. *Cancer Res*. 2022 Feb 1;82(3):349-358.
10. Bauer AT, Gorzelanny C, **Gebhardt C**, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. *Cancer Treat Rev*. 2022 Jan;102:102322.
11. Plasmeijer EI, Sachse MM, **Gebhardt C**, Geusau A, Bouwes Bavinck JN. Cutaneous Squamous Cell Carcinoma (cSCC) and Immunosurveillance - The Impact of Immunosuppression on Frequency of cSCC. *J Eur Acad Dermatol Venereol*, 33 Suppl 8, 33-37 Dec 2019
12. Gaiser MR, von Bubnoff N, **Gebhardt C**, Utikal JS. Liquid Biopsy to Monitor Melanoma Patients. *J Dtsch Dermatol Ges*, 16 (4), 405-414 Apr 2018

13. Umansky V, Blattner C, Fleming V, Hu X, **Gebhardt C**, Altevogt P, Utikal J. Myeloid-derived suppressor cells and tumor escape from immune surveillance. *Semin Immunopathol.* 2017 Apr;39(3):295-305
14. Umansky V, Blattner C, **Gebhardt C**, Utikal J. The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. *Vaccines (Basel).* 2016 Nov 3;4(4).
15. Umansky V, Utikal J, **Gebhardt C**. Predictive immune markers in advanced melanoma patients treated with ipilimumab. *Oncoimmunology.* 2016 Apr 29;5(6):e1158901.
16. Stadler S, Weina K, **Gebhardt C**, Utikal J. New therapeutic options for advanced non resectable malignant melanoma. *Adv Med Sci.* 2015 Mar;60(1):83-8.
17. Umansky V, Sevko A, **Gebhardt C**, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. *J Dtsch Dermatol Ges.* 2014 Nov;12(11):1021-7.
18. **Gebhardt C**, Näher H. Standards und Trends bei der Behandlung des malignen Melanoms. *Onkopipeline* 2009 Sep; 2(3):101-113.
19. **Gebhardt C**, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. *Biochem Pharmacol.* 2006 Nov 30;72(11):1622-31.

Books (selection)

1. **Gebhardt C**. Kapitel „Dermatoonkologie“ im Syllabus zum Update Hämatologie/Onkologie 2024, Herausgeber: Petrarsch, S. Interplan, München
2. **Gebhardt C**. Fakten kompakt Opdivo Adjuvant: zur adjuvanten Behandlung des Melanoms im resezierten Stadium IIB/C und III und IV, 2024, Thieme, München
3. **Gebhardt C**. Kapitel „Dermatoonkologie“ im Syllabus zum Update Hämatologie/Onkologie 2023, Herausgeber: Petrarsch, S. Interplan, München
4. **Gebhardt C**. Cemiplimab (Libtayo) beim fortgeschrittenen Basalzellkarzinom: Erfahrungen aus der Praxis nach HHI-Therapie 2023, Thieme, München
5. **Gebhardt C**. Kapitel „Dermatoonkologie“ im Syllabus zum Update Hämatologie/Onkologie 2022, Herausgeber: Petrarsch, S. Interplan, München
6. FN Artz, M Erdmann, M Fluck, **C Gebhardt**, A Gesierich, V Glutsch. Cemiplimab (Libtayo): die erste zugelassene Therapie beim metastasierten oder lokal fortgeschrittenen kutanen Plattenepithelkarzinom. 2021, Thieme, München
7. **Gebhardt C**. Kapitel „Dermatoonkologie“ im Syllabus zum Update Hämatologie/Onkologie 2021, Herausgeber: Petrarsch, S. Interplan, München
8. **Gebhardt C.**, Quantensprung in der dermatologischen Onkologie, Trillium Krebsmedizin, Krebsmedizin 2021; 30(4), 271-272
9. **Gebhardt C.**, Das maligne Melanom – Klassifikation, Diagnostik, Primärversorgung, Nachsorge, Trillium Krebsmedizin, Krebsmedizin 2021; 30(4), 277-285
10. **Gebhardt C.**, Adjuvante und neoadjuvante Therapie des malignen Melanoms, Trillium Krebsmedizin, Krebsmedizin 2021; 30(4), 286-290
11. **Gebhardt C.**, Malignes Melanom: Systemtherapie bei metastasierter Erkrankung – neue Studiendaten, Trillium Krebsmedizin, Krebsmedizin 2021; 30(4), 291-296
12. **Gebhardt C.**, Haalck T. Nebenwirkungsmanagement dermatoonkologischer Systemtherapien, Trillium Krebsmedizin, Krebsmedizin 2021; 30(4), 297-301
13. **Gebhardt, C**. Fakten kompakt Opdivo Adjuvant (Update): zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV. Thieme, 2021

14. **Gebhardt C.** Kapitel „Dermatoonkologie“ im Syllabus zum Update Hämatologie/Onkologie 2020, Herausgeber: Petrarsch, S. Interplan, München
15. **Gebhardt C.** Kapitel „Hauttumore“ (285-291) in Giordano FA und Wenz F. Strahlentherapie kompakt, Elsevier, München. 2019
16. **Gebhardt, C.** Fakten kompakt Opdivo Adjuvant: zur adjuvanten Behandlung des Melanoms im resezierten Stadium III und IV. Thieme, 2019
17. **Gebhardt C.** Kapitel „Hauttumore“ in Wenz F, Giordano F. Strahlentherapie, Elsevier, München. 2017
18. Reinhard R, **Gebhardt C**, Utikal J. „Kapitel 42: Malignes Melanom beim alten und geriatrischen Patienten“ in M. Ebert, N. Härtel, U. Wedding. Geriatrische Onkologie, Springer Verlag, Heidelberg
19. Bachmann K, Enk A, **Gebhardt C**, Hartmann M, Weishaar E. Kapitel: „Beschreibung von Hautbefunden“, „Basisuntersuchung: Haut & Schleimhäute“ in R. Pjontek, F. Scheibe, J. Tabatabai. Heidelberger Standarduntersuchung, Interdisziplinäre Handlungsanweisungen zur Durchführungen der körperlichen Untersuchung, Medizinische Fakultät Heidelberg / HeiCuMed, 2. Auflage, 2013